Brought to you by 
Serono licenses fertility rights to AstraZeneca's anastrozole
29 Aug 2002
Executive Summary
Serono SA has licensed exclusive worldwide rights from AstraZeneca to develop and sell anastrozole, an orally delivered aromatase inhibitor, to treat infertility.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Serono licenses fertility rights to AstraZeneca's anastrozole
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice